Entrada Therapeutics (TRDA) Projected to Post Quarterly Earnings on Thursday

Entrada Therapeutics (NASDAQ:TRDA) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.06) per share and revenue of $2.9190 million for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.38. The business had revenue of $1.30 million during the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. On average, analysts expect Entrada Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Entrada Therapeutics Trading Up 1.1%

Shares of TRDA traded up $0.18 during trading hours on Wednesday, reaching $15.93. 78,434 shares of the company’s stock traded hands, compared to its average volume of 216,266. The stock has a market cap of $618.40 million, a PE ratio of -4.60 and a beta of -0.09. The firm’s 50 day simple moving average is $12.81 and its 200-day simple moving average is $10.82. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $16.19.

Insider Activity

In other news, COO Nathan J. Dowden sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $15.33, for a total value of $229,950.00. Following the completion of the sale, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at $3,044,354.04. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Kory James Wentworth sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $12.95, for a total value of $32,375.00. Following the sale, the chief financial officer directly owned 119,010 shares of the company’s stock, valued at $1,541,179.50. This represents a 2.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 82,882 shares of company stock valued at $1,169,103 in the last ninety days. Insiders own 9.49% of the company’s stock.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Wyoming raised its position in Entrada Therapeutics by 130.9% during the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock valued at $51,000 after purchasing an additional 4,295 shares in the last quarter. Russell Investments Group Ltd. raised its position in Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after purchasing an additional 3,707 shares in the last quarter. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics during the 2nd quarter valued at $68,000. Jain Global LLC bought a new stake in Entrada Therapeutics during the 3rd quarter valued at $69,000. Finally, IHT Wealth Management LLC bought a new stake in Entrada Therapeutics during the 2nd quarter valued at $72,000. 86.39% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Friday, March 27th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Oppenheimer upped their price objective on Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a research report on Monday, April 6th. Guggenheim upgraded Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. Finally, Cantor Fitzgerald started coverage on Entrada Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Entrada Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $19.00.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.